We analyzed the clinical outcome in 90 children undergoing allogeneic PBSC transplantation from HLA-identical relative for leukemia. GvHD prophylaxis was CsA þ methotrexate in 50 and CsA7steroids in 40. Median CD34 þ cells infused were 6 Â 10 6 /kg (range, 1.4-32). Median follow-up was 60 months (range, 6-115). CI of transplantrelated mortality (TRM) was 18.474%. On multivariate analysis, high Lansky score (480) at transplantation was associated with lower TRM (HR, 0.9; Po0.0002). Relapse incidence (RI) was 33.676%. On multivariate analysis, high Lansky score at transplantation and cGvHD were associated with lower RI (HR, 0.04; Po0.0005 and HR, 0.23; Po0.03, respectively). Disease-free survival (DFS) was 57.875%. Disease status at transplantation (HR, 0.33; Po0.02), steroid treatment at day þ 90 (HR, 5.61; Po0.005) and cGvHD (HR, 0.23; Po0.005) had a significant impact on DFS in multivariate analysis. CI of cGvHD was 63.777%. Patients with cGvHD had better DFS (6575%) because of lower RI (15.776%) and similar TRM (27.474%). These data suggest acceptable long-term outcomes after allogeneic PBSC transplantation in children despite the high incidence of cGvHD. These patients had a lower risk of relapse and a better DFS. Bone Marrow Transplantation (2005) 36, 781-785.
plantation Allogeneic transplantation using PBSC produces faster hematological recovery and less early transplant-related mortality (TRM), which results in better survival, especially in adult patients transplanted in advanced phase of disease.
1,2 As a result of this, a rapid change from allogeneic bone marrow (BM) to PBSC transplantation has recently occurred in clinical practice despite high incidence of cGvHD observed in some studies. 3 In pediatric patients, mobilized PB instead of BM as a source of hematopoietic stem cells is widely used in the autologous transplantation setting. However, this rapid change in clinical practice has been slower in the allogeneic transplantation setting not only due to early concerns of donor safety as many pediatric donors are minors, but also due to concerns that the foreseeable high incidence of cGvHD may increase the TRM. Two recent papers have demonstrated that children, even the smaller ones, may safely be mobilized by granulocyte colony-stimulating factor (G-CSF) and undergo PBSC collections by apheresis. 4, 5 Regarding clinical outcomes, there is only a limited series of cases and retrospective studies reported. [6] [7] [8] [9] [10] [11] These studies suggest that allogeneic PBSC transplantation in children is similar to BM in terms of relapse incidence (RI) and TRM but with a trend toward a higher incidence of cGvHD. [9] [10] [11] Recently, a large retrospective study comparing allogeneic PBSC and BM transplantation in children and adolescents found a higher TRM in the PBSC group 12 but no long-term follow-up series have been reported. Herein, we report a long-term follow-up study analyzing the outcome in pediatric patients with hematological malignancies receiving an allogeneic PBSC-matched transplantation.
Patients, donors and methods

Patient selection
A total of, 90 pediatric patients, from Institutions belonging to the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON) and the Spanish Group for Allogeneic Peripheral Blood Transplantation (GETH) who received G-CSF-mobilized PBPC transplantation from an HLA-identical sibling donor as a first transplant for hematological malignancies between January 1995 and December 2003 were included in this study. All patients received a myeloablative preparatory regimen and an unmanipulated blood stem cell graft. Informed consent was obtained from each patient and donor or their parents. Details of blood stem cell mobilization and collection have been described previously. 4 Patients, donors and transplantation characteristics are shown in Table 1 .
Study definitions and end points
The clinical outcomes analyzed were hematological recovery, acute and chronic GvHD, TRM, RI and disease-free survival (DFS). Disease status at transplantation was considered early for patients in first remission or first chronic phase, intermediate for patients in second remission or second chronic phase and advanced for those in later remission, blast crisis or transplanted in relapse. Neutrophil engraftment was defined as the first of three consecutive days in which the absolute neutrophil count exceeded 0.5 Â 10 9 /l. Platelet recovery was defined as the first of three consecutive days in which the absolute platelet count exceeded 20 Â 10 9 /l without platelet transfusion during a 7-day period. The diagnosis of acute and chronic GvHD was based on clinical standard criteria with histologic confirmation whenever possible. 13, 14 The incidence of acute GvHD grade II or higher was evaluated in all patients. Chronic GvHD was evaluated in patients surviving at least 90 days after transplantation. Relapse was defined as hematologic or extramedullary leukemia recurrence. TRM was defined as death in continuous complete remission. Patients were censored at time of relapse or last follow-up, whichever was first. DFS was defined as survival in continuous complete remission. Relapse (any location) and death (any cause) were considered as events. Patients were censored at the last follow-up.
Statistical methods
The actuarial curves of RI and DFS were obtained using the Kaplan-Meier method 15 and the differences between groups were compared using the log-rank test. Estimates of cumulative incidence of cGvHD were calculated considering death or relapse without cGvHD as competing risks. Proportional hazard regression model was used for univariate and multivariate analyses of risk factors for cGvHD. 16 The variables considered in this analysis were patient age and gender, female donor for male patient, disease type (AML, ALL, CML), disease status at transplantation, conditioning regimen used (TBI-based vs chemotherapy-based), GvHD prophylaxis (short methotrexate þ CsA vs others), grades II-IV aGvHD (no vs yes) and number of CD34 þ and CD3 þ cells infused. Variables that were found significant on univariate analysis were included on multivariate analysis. The P value threshold for multivariate analysis was 0.1. All statistical analysis and data handling were performed with Statview 5 (SAS Institute Inc., Cary, NC, USA) for PowerPC of Macintosh (Apple Computer Inc., Cupertino, CA, USA).
Results
Hematological recovery
All patients achieved neutrophil engraftment. Median time to neutrophil recovery was 11 days (range 8-32 days). The cumulative incidence of platelet recovery (X20 Â 10 9 /l) at day 100 was 98% (95% CI: 96-100%) with a median time of 12 days (range 9-130 days). Achievement of a platelet count X50 Â 10 9 /l and X100 Â 10 9 /l took 16 days (range 9-190 days) and 37 days (range 10-300 days), respectively. The respective cumulative incidences at day 100 were 94% (95% CI: 91-97%) and 81% (95% CI: 77-85%). 
Acute and chronic GvHD
Cumulative incidence of grade II-IV aGvHD at day 100 was 25% (95% CI: 20-30% /l) (RR: 43.65; 95% CI: 3.57-532.50; P ¼ 0.003) and Lansky score below 80 (RR: 9.25; 95% CI: 1.05-100; P ¼ 0.04) had a negative impact on DFS.
Treatment-related mortality and causes of death
In all, 36 patients had died at the time of analysis. The main cause of death in the whole group was relapse of disease.
However, there was a significant difference in causes of death between patients with or without cGvHD ( Table 4) . The cumulative incidence of TRM was 18% (95% CI: 14-22%). Lansky status at transplantation was the only variable significantly associated to TRM in multivariate analysis (RR: 0.9; 95% CI: 0.85-0.95; P ¼ 0.0002).
Relapse
Cumulative incidence of relapse was 33% (95% CI: 28-38%). A high Lansky score at the time of transplantation (RR: 0.04; 95% CI: 0.009-0.26; P ¼ 0.0005) and cGvHD (RR: 0.23; 95% CI: 0.059-0,89; P ¼ 0.03) were associated with a lower probability of relapse in multivariate analysis.
Disease-free survival
The probability of DFS was 58% (95% CI: 52-64%). In multivariate analysis, early phase of disease at transplantation (RR: 0.33; 95% CI: 0.12-0.85; P ¼ 0.02) and cGvHD (RR: 0.22; 95% CI: 0.08-0.64; P ¼ 0.005) were found to be significantly associated with high probability of DFS, whereas steroid treatment by day 90 after transplantation had a negative impact on DFS (RR: 5.62; 95% CI: 1.65-19.16; P ¼ 0.005). The probability of DFS for these variables is shown in Figures 1, 2 and 3 , respectively. 
Discussion
The first reports on allogeneic PBSC transplantation in children were published in 1996 by Villa et al 6 and
Ko¨rbling et al. 7 Both studies involved a small number of patients and explored procedure feasibility. Many of the reported studies in allogeneic PBSC transplantation in children are retrospective and involved few patients. [6] [7] [8] [9] [10] [11] Results from some of these studies 8, 9 suggest that allogeneic PBSC transplantation may have advantages for engraftment kinetics over allogeneic bone marrow transplantation without an increased incidence of severe acute GvHD. Others 10, 11 suggest that PBSC transplantation outcomes are at least similar to BM as an allogeneic stem cell source in terms of TRM, RI and DFS. Only one retrospective study recently published found higher TRM in patients who underwent PBSC transplantation compared to BM. 12 Most studies found a trend toward or a high incidence of cGvHD in pediatric patients transplanted using PBSC, [9] [10] [11] but no prospective randomized studies have been published to date. Despite this, data from the IBMTR suggest that PBSC grafts are increasingly used instead of BM for allogeneic transplantation, for a total of 30% of allogeneic transplantation in children worldwide. One of the main problems in further evaluation of allogeneic PBSC transplantation in children for years has been the lack of safety data regarding normal pediatric donors. Current data from the literature suggest that mobilization and collection of PBSC appear to be safe for pediatric donors and to yield sufficient numbers of hematopoietic progenitors for transplantation even if the recipient is an adult. 4, 5 Another matter of concern is the issue of high incidence of cGvHD. In the IBMTR study, 12 authors argued that higher mortality in the PBSC grafts was likely due to higher cGvHD. They also stated that as cGvHD is lower in children than in adults after BM transplants, a higher risk of mortality from cGvHD may offset any measurable benefit in the early period of transplantation. However, data recently published suggest that pediatric patients with cGvHD had a better survival because of a lower probability of leukemia relapse. 17 The present study was designed to evaluate long-term follow-up outcomes in pediatric patients undergoing allogeneic PBSC transplantation after myeloablative conditioning. The results reported here are at least comparable to, if not better than, those reported by the IBMTR study 12 for the PBSC group in terms of TRI, RI and DFS. However, the observed incidence of cGvHD in the mentioned study was 33%, whereas in our study it is 63%. This may be due to a longer follow-up in our series. Although, median time to cGvHD is similar to that observed in BM patients, risk of cGvHD still increases during the second year after transplantation. Thus, patients should be closely followed and evaluated for cGvHD for at least 2 years after transplantation and especially at the time of cessation of immunotherapy. Chronic GvHD is the major cause of late mortality in patients surviving beyond 2 years after transplantation. 18 However, the clinical consequences of cGvHD are not always negative. Chronic GvHD is associated with lower leukemia relapse after bone marrow and PBSC transplantation. 17, 19 This graft-versus-leukemia effect (GvL) associated with cGvHD was more clearly present in patients transplanted in advanced stage of disease. 20, 21 The GvL effect is poorly understood but at least two different mechanisms have been proposed to explain the hypothetical stronger GvL effect associated with PBSC transplantation. One is related to the high number of without steroid 69% (95% CI: 63-75%) and with steroid 16% (95% CI: 7-25%); log-rank test, P-value o0.0001.
hematopoietic progenitors infused resulting in a more rapid expansion of normal hematopoiesis. 22 The other is related to the high number of donor CD3 þ cells in the graft. High amounts of donor CD3 þ cells may provide a more prominent and protracted GvL reaction. 23 Recently, the number of CD3 þ cells in the graft has been considered of relevance in the outcome of allogeneic PBSC transplantation. 24 In fact, in our study, the number of CD3 þ cells grafted was a risk factor for cGvHD. However, no conclusions have been reached regarding this issue in several randomized studies due to the limited number of cGvHD cases. 3 The T-cell dose for allogeneic PBSC grafts in children might be more important than it is in adults and a high number of T cells in the pediatric PBSC grafts may have a negative impact on clinical outcomes as pointed out by others. 25 We realized that our data should be considered with caution due to the retrospective nature of the study. However, we believe that this study provides useful information regarding long-term outcome in the controversial area of allogeneic PBSC transplantation in children, identifying risk factors for TRM, RI and DFS.
Our study also confirms the high incidence of cGvHD previously reported by us 17 and others. 9, 12 However, this was not associated with a significant increase of TRM.
We agree with others 11, 12 that the use of allogeneic PBSC transplantation in children should be evaluated in controlled clinical studies and should be reserved only for patients with hematological malignancies due to the high incidence of cGvHD.
